TY - JOUR T1 - Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2020-218942 SP - annrheumdis-2020-218942 AU - Seza Ozen AU - Fabrizio De Benedetti Y1 - 2020/09/27 UR - http://ard.bmj.com/content/early/2020/09/27/annrheumdis-2020-218942.abstract N2 - We thank Satis et al1 for their interest in our article,2 and will try to address their queries. Our colleagues suggest that flares with musculoskeletal symptoms as predominant signs may not be remembered by the patients when they report them. We reported that in Epoch 4 of the CLUSTER study, &gt;90% of the patients treated with canakinumab experienced no flares or one flare throughout the 72-week period, while a median of 17.5 flares per year was reported before baseline. As detailed in the methods section and according to the study protocol, during the trial patients were considered to experience a flare when they present with a physician global assessment (which includes the assessment of musculoskeletal symptoms) ≥2 and C-reactive protein (CRP) ≥30 mg/L. On the other hand, if the phenomenon that Satis et al1 mentioned occurred when patients reported the number of flares before the trial, it could have potentially led to an underestimation of the number of flares … ER -